Business
Publication of New Research
Publication of New Research.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8384X\n Roquefort Therapeutics PLC\n 10 January 2022\n \n \n \n \n 10 January 2022\n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n Publication of New Research\n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to inform shareholders that a new research note on the Company has recently been published by Pitt Street Research.\n \n \n \n \n \n The research can be found on the Company's website via the link below:\n \n \n \n \n https://www.roquefortinvest.com/research-reports\n \n \n \n \n \n \n \n ENDS\n \n \n \n \n \n Enquiries:\n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n \n \n Stephen West (Chairman)\n \n \n \n \n +44 (0)20 3290 9339\n \n \n \n \n \n \n \n \n \n Buchanan (Public Relations)\n \n \n Ben Romney / Jamie Hooper / George Beale\n \n \n \n \n \n Optiva Securities Limited (Broker)\n \n \n \n \n \n \n \n +44 (0)20 7466 5000\n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n For further information on Roquefort Therapeutics, please \n visit \n \n \n www.roquefortinvest.com\n \n \n and @roquefortinvest on Twitter.\n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n \n \n About Roquefort Therapeutics\n \n \n Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd (\"Lyramid\"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation. \n \n \n \n \n \n Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyra...